To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366)

Inclusion Criteria: * Allergic rhinitis symptoms: sneezing, rhinorrhea, obstruction of the nasal passages, itchy nose and throat, and conjunctival * Male or female outpatient 20 years of age and older * Patients with the following signs and symptoms of asthma and allergic rhinitis: history of cough, wheezing, shortness of breath, positive methacholine bronchoprovocation test Exclusion Criteria: * Active, acute or chronic, pulmonary disorder (besides asthma) documented by history, physical examination, or chest x-ray. history of anaphylactic or hypersensitive to study drug * Requires oral, intravenous, or intramuscular corticosteroids on daily routine basis * Started on immunotherapy within six months before the pre-study visit and/or the dose of immunotherapy is expected to change over the course of the study * Treated with montelukast within 3 months before enrollment * Unable to perform acceptable, reproducible spirometry and peak flow measurement * Unresolved symptoms and signs of an upper respiratory tract infection (uri) within 2 weeks prior to visit 1